Wuilleme S, Robillard N, Lodé L, Magrangeas F, Beris H, Harousseau J-L, Proffitt J, Minvielle S, Avet-Loiseau H
Laboratory of Hematology, University Hospital, Nantes, France.
Leukemia. 2005 Feb;19(2):275-8. doi: 10.1038/sj.leu.2403586.
Ploidy appears as an important parameter in both the biology and the clinical evolution of multiple myeloma. However, its evaluation requires either a successful karyotyping (obtained in 30% of the patients) or a DNA index calculation by flow cytometry (not routinely performed in myeloma). We validated a novel method based on interphase fluorescence in situ hybridization that can be utilitized to analyze almost all the patients. The method was very specific and sensitive for the detection of hyperdiploidy. Extended studies showed that most recurrent 14q32 translocations occur in nonhyperdiploid clones, and that deletions of chromosome 13 were less frequently observed in hyperdiploid clones (48 vs 66%). Further large studies are ongoing to evaluate the prognostic value of ploidy in myeloma.
倍性在多发性骨髓瘤的生物学特性及临床演变过程中似乎都是一个重要参数。然而，对其进行评估要么需要成功进行核型分析（仅30%的患者能获得结果），要么需要通过流式细胞术计算DNA指数（骨髓瘤患者一般不常规进行此项检查）。我们验证了一种基于间期荧光原位杂交的新方法，该方法可用于分析几乎所有患者。此方法在检测超二倍体时具有高度特异性和敏感性。进一步的研究表明，大多数常见的14q32易位发生在非超二倍体克隆中，并且13号染色体缺失在超二倍体克隆中较少见（分别为48%和66%）。目前正在开展进一步的大型研究，以评估倍性在骨髓瘤中的预后价值。
